172 related articles for article (PubMed ID: 31047039)
21. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.
Davidson M; Chau I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):327-338. PubMed ID: 29431018
[TBL] [Abstract][Full Text] [Related]
22. [Adenocarcinoma arising in gastroesophageal junction: a reappraisal].
Zhang XH
Zhonghua Bing Li Xue Za Zhi; 2007 Jun; 36(6):363-5. PubMed ID: 17822618
[No Abstract] [Full Text] [Related]
23. Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma.
Wang X; Li X; Cheng Y; Sun X; Sun X; Self S; Kooperberg C; Dai JY
Hum Genomics; 2015 Sep; 9(1):22. PubMed ID: 26374103
[TBL] [Abstract][Full Text] [Related]
24. Genomic pathobiology of gastric carcinoma.
Katoh H; Ishikawa S
Pathol Int; 2017 Feb; 67(2):63-71. PubMed ID: 28004449
[TBL] [Abstract][Full Text] [Related]
25. Allelic deletion in 11p15 is a common occurrence in esophageal and gastric adenocarcinoma.
Moskaluk CA; Rumpel CA
Cancer; 1998 Jul; 83(2):232-9. PubMed ID: 9669804
[TBL] [Abstract][Full Text] [Related]
26. Histopathologic classification of adenocarcinoma of the esophagogastric junction.
Baldus SE
Recent Results Cancer Res; 2010; 182():29-38. PubMed ID: 20676869
[No Abstract] [Full Text] [Related]
27. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
28. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
29. The Molecular Biologic Basis of Esophageal and Gastric Cancers.
Pennathur A; Godfrey TE; Luketich JD
Surg Clin North Am; 2019 Jun; 99(3):403-418. PubMed ID: 31047032
[TBL] [Abstract][Full Text] [Related]
30. CpG island hypermethylation in progression of esophageal and gastric cancer.
Sato F; Meltzer SJ
Cancer; 2006 Feb; 106(3):483-93. PubMed ID: 16362978
[TBL] [Abstract][Full Text] [Related]
31. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma.
Nagaraja AK; Kikuchi O; Bass AJ
Cancer Discov; 2019 Dec; 9(12):1656-1672. PubMed ID: 31727671
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers in lung adenocarcinoma: a decade of progress.
Sholl LM
Arch Pathol Lab Med; 2015 Apr; 139(4):469-80. PubMed ID: 25255293
[TBL] [Abstract][Full Text] [Related]
33. Tumor genomics vs. tumor genetics: a paradigm shift?
Meltzer SJ
Gastroenterology; 2001 Sep; 121(3):726-9. PubMed ID: 11522757
[No Abstract] [Full Text] [Related]
34. Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis.
Romano C; Di Gregorio S; Pennisi MS; Tirrò E; Broggi G; Caltabiano R; Manzella L; Ruggieri M; Vigneri P; Di Cataldo A
Mol Biol Rep; 2022 Sep; 49(9):9059-9064. PubMed ID: 35715605
[TBL] [Abstract][Full Text] [Related]
35. Crescendos and decrescendos: gastric and esophageal cancers.
Ajani JA
J Natl Compr Canc Netw; 2011 Aug; 9(8):811-3. PubMed ID: 21900215
[No Abstract] [Full Text] [Related]
36. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome.
Lim SM; Lim JY; Cho JY
World J Gastroenterol; 2014 Feb; 20(8):2042-50. PubMed ID: 24587678
[TBL] [Abstract][Full Text] [Related]
38. Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction.
Lurje G; Lenz HJ
Recent Results Cancer Res; 2010; 182():179-91. PubMed ID: 20676881
[TBL] [Abstract][Full Text] [Related]
39. Next generation sequencing technologies in cancer diagnostics and therapeutics: A mini review.
Li W; Zhao K; Kirberger M; Liao W; Yan Y
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(5):91-102. PubMed ID: 26522064
[TBL] [Abstract][Full Text] [Related]
40. Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.
Nowak JA; Yurgelun MB; Bruce JL; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; Agoston AT; Srivastava A; Ogino S; Kuo FC; Lindeman NI; Dong F
J Mol Diagn; 2017 Jan; 19(1):84-91. PubMed ID: 27863258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
